Novo Nordisk opens to New York listing while Novo Nordisk stock falls 1.10 percent

Published on 10/01/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted sales rose 7.00 percent to DKK 78.49 billion. Novo Nordisk stock costs EUR 33.20 on October 1, 2026 after EUR 33.57.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk (DK0062498333) was trading at EUR 33.20 at Lang & Schwarz on October 1, 2026 at 11:30 a.m. CEST, down 1.10 percent versus the EUR 33.57 prior close. According to MarketScreener in a September 23, 2026 report carrying Reuters material, CEO Mike Doustdar said Novo sees advantages in upgrading its New York listing. The combination of a strategic U.S. market signal and a negative intraday quote leaves execution, rather than visibility alone, as the central issue for the stock.

New York listing enters the debate

Doustdar said a direct New York listing could replace the American depositary receipts currently used by U.S. investors, according to MarketScreener. The report describes the idea as part of an effort to raise Novo Nordisk's profile in the United States, but it does not present a completed listing decision.

The operating backdrop is mixed. Yahoo Finance reported that adjusted sales reached DKK 78.49 billion in the second quarter of 2026, up 7.00 percent at constant exchange rates. The same source said adjusted operating profit increased 11.00 percent in the quarter, while U.S. operations grew 4.00 percent and obesity care sales rose 16.00 percent.

Growth meets a lower outlook

Novo Nordisk's full-year 2026 outlook calls for adjusted sales growth of 0.00 percent to minus 6.00 percent at constant exchange rates, according to Yahoo Finance. That range contrasts with the second-quarter sales increase and shows why stronger GLP-1 volume has not fully offset pricing pressure and changing competitive conditions.

Analyst expectations also remain divided. MarketScreener reported on September 22, 2026 that Jefferies cut its target to DKK 275 from DKK 285 and retained a Hold rating. Jefferies cited continuing uncertainty ahead of semaglutide's patent expiry and reduced its valuation multiple to 12.50 times from 13.50 times.

Next results set the next test

MarketScreener lists Novo Nordisk's third-quarter 2026 earnings release for November 3, 2026. That date gives investors a defined checkpoint for testing whether the 7.00 percent second-quarter sales growth can carry into the second half while the full-year outlook still permits a decline.

Novo Nordisk was trading at EUR 33.20 at Lang & Schwarz on October 1, 2026 at 11:30 a.m. CEST, down 1.10 percent versus the EUR 33.57 prior close. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.